No Data
Key points of interest for PTS on the 6th = Fujitsu, Bike King, Asteria, Next Stage ETC.
▽Fujitsu <6755.T>, TOB (Stock Public Purchase) by Paloma Reem Holdings. The purchase price is 2808 yen. ▽Bike King <3377.T>, raised the consolidated operating profit Financial Estimates for the fiscal year ending November 2024 from 120 million yen to 290 million yen (previous period had a loss of 170 million yen). The auction market has remained more stable than expected. ▽Asteria <3853.T>, increased the consolidated operating profit Financial Estimates for the fiscal year ending March 2025 to a profit of 600 million yen (the previous period had a loss of 3.64 billion yen, previous estimates).
FunPep: Notice regarding publication of earnings forecasts
FunPep Sees FY Parent Pretax Loss Y796.00M
FunPep Sees FY Net Y826.00M
DWTI, Architects SJ and others.
＜1447＞ Acquisition and cancellation of all remaining subscription rights of the 4th series (with exercise price adjustment clause) of SAAFD. ＜3557＞ Large exercise of the 9th subscription rights (with exercise price adjustment clause) of U&C from the 4th, number of shares delivered, 0.07 million, 2000 shares. ＜4576＞ Approval obtained in Thailand for the glaucoma and ocular hypertension treatment "Grau Alpha combination eye drops (domestic product name)" of DWTI. ＜4586＞ Termination of joint research contract with Medrec Fanpepp. ＜4881＞ Soleasia's downward revision, current period operations.
Fanpep - Initiation of the additional Phase 3 clinical trial for the functional peptide "SR-0379".
Fanpeep <4881> announced on the 23rd that the designated investigation by the Independent Administrative Institution Pharmaceuticals and Medical Devices Agency (PMDA) for the functional peptide "SR-0379" being developed for skin ulcers has been completed, and clinical trial phase 02 will begin. SR-0379 is a developmental compound consisting of 20 amino acids. For the treatment of skin ulcers where the skin barrier function is compromised and various bacteria adhere to the wound, controlling bacteria and infection is essential.